Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
← catalyst calendarNCT07444320 · readout ≤ 558 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
200estimated
Sites
4
Countries
Croatia, Czechia, Hong Kong +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-12 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
Intervention
- Device: FARAPULSE™ Pulsed Field Ablation (PFA) System
Primary outcomes
what the primary-completion date above is the date OFDevice or procedure-related Composite Adverse Events (CAEs)
measured Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60
Acute Procedural Success
measured During the Ablation Procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed